Michelson Medical Research Foundation, Inc.
LOS ANGELES, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$112.5M2026 Q3
Positions21
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.74.6%
Michelson Medical Research Foundation, Inc. reported 21 positions worth $112.5M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: AMRZ (13.3%).
10 / 21 positions shown
| # | Symbol | Company | Value ↓ | % Port. | Shares | 1Y | YTD | Since reported |
|---|---|---|---|---|---|---|---|---|
| ▸ 1 | AMRZ | $15.0M | 13.29% | 400,000 | — | — | +8.4% | |
| ▸ 2 | IVE | $11.8M | 10.53% | 51,905 | — | — | +5.0% | |
| ▸ 3 | VEA | $11.2M | 9.93% | 158,160 | — | — | — | |
| ▸ 4 | ISRG | $8.5M | 7.59% | 21,000 | — | — | +7.7% | |
| ▸ 5 | VWO | $7.6M | 6.73% | 127,630 | — | — | — | |
| ▸ 6 | IBB | $7.4M | 6.57% | 35,095 | — | — | — | |
| ▸ 7 | CNNE | $7.4M | 6.55% | 480,600 | — | — | +13.9% | |
| ▸ 8 | IWC | $6.5M | 5.81% | 35,385 | — | — | — | |
| ▸ 9 | KRE | $4.4M | 3.92% | 63,510 | — | — | +4.0% | |
| ▸ 10 | MANU | $4.2M | 3.72% | 200,000 | — | — | +6.0% |
Read the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does Michelson Medical Research Foundation, Inc. hold as of Q3 2026?
Michelson Medical Research Foundation, Inc. reported 21 positions worth $112.5M in its Q3 2026 13F filing. Largest positions: AMRZ (13.3%), IVE (10.5%), VEA (9.9%), ISRG (7.6%) and VWO (6.7%).
What did Michelson Medical Research Foundation, Inc. buy in Q3 2026?
No previous quarter is available yet; the comparison appears with the next filing.
What did Michelson Medical Research Foundation, Inc. sell in Q3 2026?
No previous quarter is available yet.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.